Abstract: Provided are an exosome preparation formed by secretion by a mast cell cultured in vitro, a preparation method of an exosome therein, an exosome containing Fc?RI protein on an outer surface thereof and in a substantially unbound state, and uses of the exosome preparation or exosome in a method for inhibiting mast cell activation in vitro and in preparing a drug for treating an IgE-mediated disease.
Abstract: The invention relates to cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection. In particular, the invention provides a cyclosporine liquid formulation for use as an aerosol for inhalation in a method of preventing or treating pulmonary chronic graft rejection in single lung transplanted patients. The formulation is preferably administered once or twice daily. The formulation may be aerosolized with a nebulizer that comprises features for monitoring the time, date and duration of inhalation by the patient, in order to monitor patient adherence. The formulation according to the invention may be combined with standard immunosuppressants and corticosteroids.
Abstract: The disclosure features novel methods of producing nucleic acid lipid nanoparticle (LNP) compositions employing a modifying agent after formation of a precursor nucleic acid lipid nanoparticle, the produced compositions thereof, and methods involving the nucleic acid lipid nanoparticles useful in the delivery of therapeutics and/or prophylactics, such as a nucleic acid, to mammalian cells or organs to, for example, to regulate polypeptide, protein, or gene expression.
Type:
Grant
Filed:
August 31, 2018
Date of Patent:
September 5, 2023
Assignee:
ModernaTX, Inc.
Inventors:
Joseph Schariter, Kimberly Hassett, Mike Smith, Orn Almarsson, Luis Brito
Abstract: A method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and a suspension obtained according to said method, where the freeze-dried product has been subjected to a thermal treatment.
Type:
Grant
Filed:
July 25, 2022
Date of Patent:
August 15, 2023
Assignee:
Bracco Suisse SA
Inventors:
Philippe Bussat, Anne Lassus, Jean Brochot, Michel Schneider, Feng Yan
Abstract: Lipid formulation particularly for preparing stable gas-filled microvesicles, comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine-PEG5000 (DPPE-PEG5000) and palmitic acid in an advantageous relative molar ratio. The formulation is useful in particular for therapeutic application with ultrasounds.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
August 8, 2023
Assignee:
Bracco Suisse SA
Inventors:
Philippe Bussat, Samir Cherkaoui, David Lazarus, Eric Allémann, Michel Schneider, Christian Guillot
Abstract: The semisolid oral dispersions include hydrophilic active agent particles in hydrophobic phase. The hydrophilic active agent particles can include bleaching agents, antimicrobial agents, anticalculus agents, and/or combinations thereof. The hydrophilic active agent particle can have a solubility in water of at least about 20 parts, by weight of the particles, in about 100 parts, by weight, of water.
Type:
Grant
Filed:
April 8, 2020
Date of Patent:
August 1, 2023
Assignee:
The Procter & Gamble Company
Inventors:
Paul Albert Sagel, Jayanth Rajaiah, Michael David Curtis
Abstract: Provided herein are immunomodulatory nanoparticles, compositions containing the same, and methods of use thereof, such as for the treatment of traumatic brain injury.
Abstract: A method of macular disease treatment (500) may include introducing nanocapsules into a body of a patient (502). The nanocapsules may be introduced such that the nanocapsules circulate through at least a portion of a body of the patient. A therapeutic substance and a colorant may be encapsulated into the nanocapsules. After a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include emitting a pulsed laser radiation through a pupil of the eye (504). Additionally, after a portion of the nanocapsules enters choroidal neovessels of an eye of the patient, the method may include heating the portion of the nanocapsules present in the eye (506) such that at least a portion of the nanocapsules transfer phase and release the therapeutic substance.
Abstract: The disclosure relates to nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide. Aspects of the disclosure further relate to uses of nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide, for improving wound healing in a subject.
Type:
Grant
Filed:
October 31, 2018
Date of Patent:
July 11, 2023
Assignee:
ModernaTX, Inc.
Inventors:
Kenny Mikael Hansson, Kerry Benenato, Maria Wågberg, Annika Pålsson, Regina Fritsche-Danielson
Abstract: Spherical nucleic acids (SNA) carrying self-aggregating oligonucleotides are described herein. Compositions of the SNA include discrete nanostructures that are not aggregated. Related methods are also described.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
July 11, 2023
Assignee:
Exicure Operating Company
Inventors:
Richard Kang, Subbarao Nallagatla, Bart Anderson, Ekambar Kandimalla
Abstract: A graffiti removal system and a method of removing graffiti are provided.The graffiti removal system comprises a liquid comprising 4-50 wt % glyceride wherein the glyceride is the condensation reaction product of at least 1.10 moles of a mixture of acids to no more than 2.1 moles of the mixture of acids per mole of glycerin. The mixture of acids comprises at least 0.275 to no more than 0.990 moles of a first acid comprising a branched acid with 16-20 aliphatic carbons; at least 0.250 to no more than 0.810 moles of a second acid comprising an alkyl acid with 9-11 carbons and at least 0.250 to no more than 0.810 moles of a third acid comprising an alkyl acid with 7-9 carbons. The third acid has a lower molecular weight than the second acid. The graffiti removal system also has 6-45 wt % surfactant, optionally up to 5-90 wt % graffiti removal agent and up to 90 wt % solvent. The liquid has a BYV of at least 50 dyn/cm2.
Type:
Grant
Filed:
September 8, 2021
Date of Patent:
July 4, 2023
Assignee:
Ethox Chemicals, LLC
Inventors:
Edward T. Borish, Stephanie Anderson, Charles F. Palmer, Jr.
Abstract: A three-dimensional, biocompatible scaffold precursor composition for room-temperature printing a bio-compatible polymer/hydroxyapatite composite scaffold includes a room-temperature slurry, comprising a mixture of a sold phase that includes a mixture of tetracalcium phosphate (TTCP; Ca4(PO4)2O) and dicalcium phosphate anhydrous (DCPA; CaHPO4), and a liquid phase that includes a polymer in a solvent. The solvent may be Ethanol (EtOH) or Tetrahydrofuran (THF), and the polymer may be polyvinyl butyral (PVB), polycaprolactone (PCL), or poly lactic-co-glycolic acid (PLGA). The slurry is printed at room temperature in aqueous phosphate (NaH2PO4) bath, which works as hardening accelerator, forming the polymer/hydroxyapatite composite scaffold.
Type:
Grant
Filed:
June 5, 2020
Date of Patent:
June 27, 2023
Assignee:
ADA Science and Research Institute LLC
Inventors:
Stella Alimperti, Yoontae Kim, Eun-Jin Lee, Laurence C Chow, Shozo Takagi
Abstract: Provided are a liposome composition which has a practically required long-term preservation stability, and which has a release rate of a drug on the order of several tens of hours due to releasability of a drug being able to be suitably controlled by rendering an inner water phase hyper-osmotic; and a method for producing the same. According to the present invention, it is possible to provide a liposome composition, including liposomes each of which has an inner water phase and an aqueous solution which constitutes an outer water phase and in which the liposomes are dispersed, in which the content of cholesterols is 10 mol % to 35 mol % with respect to the total amount of lipid components in the liposome composition, and each of the liposomes encapsulates a drug in a dissolved state, and an osmotic pressure of the inner water phase is 2-fold to 8-fold relative to the osmotic pressure of the outer water phase.
Type:
Grant
Filed:
December 15, 2020
Date of Patent:
June 27, 2023
Assignee:
FUJIFILM Corporation
Inventors:
Makoto Ono, Kohei Ono, Takeshi Matsumoto, Mikinaga Mori
Abstract: The present invention relates to the field of lipid nanoparticles (LPN); more specifically comprising an ionisable lipid, a phospholipid, a sterol, a PEG lipid and one or more nucleic acids. The LNP's of the present invention are characterized in having a minimal average diameter of about 140 nm, thereby inducing a more potent immune response. The present invention provides use of the LNPs for immunogenic delivery of nucleic acid molecules, specifically mRNA; thereby making them highly suitable for use in vaccines, such as for the treatment of cancer or infectious diseases. Finally, methods are provided for preparing such LNP's.
Abstract: Biofunctionalized nanocomposites comprised of a core nanoparticle formed of Prussian blue materials, a shell obtained by partially or completely encapsulating the Prussian blue core with a biocompatible coating, and at least one biomolecule attached to, or absorbed to, the biocompatible coating and uses thereof.
Type:
Grant
Filed:
March 19, 2019
Date of Patent:
June 13, 2023
Assignee:
The George Washington University
Inventors:
Rohan Fernandes, Elizabeth Sweeney, Juliana Cano-Mejia
Abstract: A sensor that may be implanted within a living animal (e.g., a human) and may be used to measure an analyte (e.g., glucose or oxygen) in a medium (e.g., interstitial fluid, blood, or intraperitoneal fluid) within the animal. The sensor may include a sensor housing and an analyte indicator covering at least a portion of the sensor housing. The sensor may include a drug-eluting matrix that covers at least a portion of the analyte indicator. The drug-eluting matrix may include one or more openings configured to allow the medium to pass through the drug-eluting matrix and come into contact with the analyte indicator. The sensor may include one or more therapeutic agents. The one or more therapeutic agents may reduce deterioration of the analyte indicator. The one or more therapeutic agents may be incorporated within the drug-eluting matrix.
Type:
Grant
Filed:
November 1, 2019
Date of Patent:
June 13, 2023
Assignee:
Senseonics, Incorporated
Inventors:
Philip Huffstetler, Sanat Mohanty, Robert Attwood
Abstract: The present disclosure is directed to protocells or nanoparticles, which are optionally coated with a lipid bilayer, which can be used for targeting bone tissue for the delivery of bioactive agents useful in the treatment and/or diagnosis of bone cancer, often metastatic bone cancer which often occurs secondary to a primary cancer such as prostate cancer, breast cancer, lung cancer and ovarian cancer, among numerous others. These protocells or nanoparticles target bone cancer especially metastatic bone cancer with bioactive agents including anticancer agents and/or diagnostic agents for purposes of treating, diagnosing and/or monitoring the therapy of the bone cancer. Osteotropic protocells or nanoparticles, pharmaceutical compositions comprising a population of osteotropic protocells or nanoparticles and methods of diagnosing, treating and/or monitoring therapy of bone cancer are representative aspects.
Type:
Grant
Filed:
January 6, 2017
Date of Patent:
June 13, 2023
Inventors:
Paul N. Durfee, Charles Jeffrey Brinker, Yu-Shen Lin, Hon Leong
Abstract: The present invention relates to a composition according to the present invention comprises: (a) at least one particle comprising at least one cationic polymer, at least one anionic polymer, and at least one hydrophilic or water-soluble UV filter; and (b) at least one physiologically acceptable volatile medium. The composition according to the present invention is stable, and can have a variety of cosmetic functions. For example, the composition according to the present invention can prepare a film which can have cosmetic effects such as UV filtering, as well as absorbing or adsorbing malodor, changing the appearance of a keratin substrate such as skin, changing the feel to the touch of the keratin substrate, and/or protecting the keratin substrate from, for example, dirt or pollutants.